Digital Public Defence: Siv Hege Lyngstad
Cand.med. Siv Hege Lyngstad at Institute of Clinical Medicine will be defending the thesis “A 10-year perspective on apathy development in psychotic disorders: Genetic risk and early predictors, associations with depression, and functional outcome” for the degree of PhD (Philosophiae Doctor).
Photo: Ingar Sørensen
The public defence will be held as a video conference over Zoom.
The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.
Due to copyright reasons, an electronic copy of the thesis must be ordered from the faculty. In order for the faculty to have time to process the order, it must be received by the faculty no later than 2 days prior to the public defence. Orders received later than 2 days before the defence will not be processed. Inquiries regarding the thesis after the public defence must be addressed to the candidate.
Digital Trial Lecture – time and place
- First opponent: Associate Professor and Consultant Psychiatrist John Lyne, Royal College of Surgeons in Ireland and Wicklow Mental Health Services
- Second opponent: Assistant Professor and Senior Researcher Lisette van der Meer, University of Gröningen and Lentis Psychiatric Institute
- Third member and chair of the evaluation committee: Associate Professor and Senior Consultant Eva Albertsen Malt, University of Oslo
Chair of the Defence
Professor Emeritus Svein Friis, University of Oslo
Consultant Ann Færden, Oslo University Hospital
The thesis aims were to explore 1) genetic underpinnings of apathy in schizophrenia spectrum disorders (SZ) and healthy controls (HC), 2) prevalence of persistent apathy (PA), persistent depression (PD) and associations with functioning in a 1-year follow-up study of first-episode psychosis (FEP), 3) predictors and development of apathy, and associations with functioning in a 10-year follow-up study of FEP and HC.
In HC, apathy was stable and low during the 10-year follow-up. In FEP, apathy decreased the first year and then remained stable. The duration of untreated psychosis (DUP), baseline apathy and depression scores were positively associated with apathy development. The effects of DUP and baseline apathy were enduring, but the effect of depression abated. Almost 40% had PA and/or PD the first year. A significant overlap of PA and PD was found in 11%. Having PA, PD or both was associated with severely impaired functioning, compared to having no persistent symptoms. Apathy showed negative cross-sectional associations with functioning during the 10-year follow-up. In SZ and HC, apathy showed non-significant associations with a schizophrenia polygenic risk score (SZ PRS). SZ PRS did not contribute to the explained variance in apathy in SZ.
The consistent, negative associations with functioning affirm the enduring impact of apathy in FEP. The first year may be a critical period. Here, apathy is less cemented and maybe more responsive to treatment. Predictors of an unfavorable apathy course present early and may help clinicians identify a vulnerable subgroup in FEP. After one year, individuals with PA, PD, or both, have severe functional impairments. Thus, one should explore depressive symptoms in those with apathy and vice versa, use rating scales that reliably discriminate these similar phenotypes, and treat depression if present. Apathy may not be linked to the common genetic architecture of SZ. Research into environmental factors underlying apathy is warranted.
Contact the research support staff.